Pipeline · FDA response expected 2026
CagriSema: the semaglutide successor to watch
CagriSema — cagrilintide combined with semaglutide — is the furthest along of the next-generation obesity combinations, with roughly 23% weight loss in its pivotal programme and an FDA response expected during 2026. It is the one to watch if you are already on semaglutide.
What it combines
Semaglutide you know. Cagrilintide is an amylin analogue — a different satiety pathway from GLP-1 entirely. The rationale is that two mechanisms acting on appetite by different routes should outperform either alone, and roughly 23% is the evidence for that proposition. It sits above approved semaglutide monotherapy and below retatrutide's triple-agonist topline, which is about where a two-mechanism combination would be expected to land.
Why it matters for what you pay
Novo Nordisk competes in the US weight-management market largely on semaglutide. A higher-efficacy successor changes the position of the existing product, and historically a predecessor's pricing and promotional behaviour changes when a successor launches.
That matters more now than it would have six months ago, because brand pricing has already moved: roughly $350 a month through the federal platform and a $50 Medicare copay for eligible patients. A successor arriving into that structure is a different event from one arriving into $1,000-a-month list pricing.
And for compounded semaglutide
A combination product is materially harder to copy than a single molecule. The compounded market that grew around semaglutide during the shortage does not extend straightforwardly to a two-component combination with its own approved ratio and titration. If the market moves toward combinations, the compounded lane narrows for reasons that have nothing to do with regulation.
What is not yet known
No approval, no launch date, no US price. We have put no CagriSema figures into the dataset because there are none to put in. When there are, they will carry a capture date and an evidence status like every other figure here.
Verified . Regulatory positions, prices and trial results move — check the primary source before relying on a date. Compounded tirzepatide and semaglutide are not FDA-approved products.
Questions
What is CagriSema?
A combination of cagrilintide, an amylin analogue, with semaglutide. It showed approximately 23% weight loss in its pivotal programme and an FDA response is expected during 2026.
Is CagriSema better than semaglutide alone?
Its pivotal result of roughly 23% weight loss sits above approved semaglutide monotherapy. Whether it is better for any individual is a clinical question, and it is not yet approved.
How much will CagriSema cost?
No US price has been announced. For context, brand GLP-1 pricing has already moved to roughly $350 a month through the federal platform, with a $50 Medicare copay for eligible patients.